# Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer

> **NCT00407563** · PHASE2 · COMPLETED · sponsor: **Accelerated Community Oncology Research Network** · enrollment: 48 (actual)

## Conditions studied

- Epithelial Ovarian Cancer
- Primary Peritoneal Carcinoma

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Abraxane

## Key facts

- **NCT ID:** NCT00407563
- **Lead sponsor:** Accelerated Community Oncology Research Network
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2012-04-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00407563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00407563, "Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00407563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*